Matrix metalloprotease-9 inhibition improves amyloid β-mediated cognitive impairment and neurotoxicity in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 1, 2009, Pages 14-22

  Mizoguchi, Hiroyuki ^a,b   Takuma, Kazuhiro ^a,c   Fukuzaki, Emiko ^a   Ibi, Daisuke ^a,d   Someya, Eiichi ^a   Akazawa, Ko Hei ^a   Alkam, Tursun ^d   Tsunekawa, Hiroko ^d   Mouri, Akihiro ^d   Noda, Yukihiro ^e   Nabeshima, Toshitaka ^e   Yamada, Kiyofumi ^a,d  

^a KANAZAWA UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e MEIJO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[25-35]; AMYLOID BETA PROTEIN[40-1]; GELATINASE A; GELATINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GLIA CELL; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NERVE CELL; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RECOGNITION;

AMYLOID BETA-PEPTIDES; ANIMALS; CELLS, CULTURED; COGNITION DISORDERS; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED ICR; MICE, KNOCKOUT; PROTEASE INHIBITORS;

EID: 70349330693     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.154724     Document Type: Article

References (40)

1. Alkam T, Nitta A, Mizoguchi H, Itoh A, and Nabeshima T (2007) A natural scavenger of peroxynitrites, rosmarinic acid, protects against impairment of memory induced by Abeta(25-35). Behav Brain Res 180:139-145. (Pubitemid 46719420)
2. Asahina M, Yoshiyama Y, and Hattori T (2001) Expression of matrix metalloproteinase- 9 and urinary-type plasminogen activator in Alzheimer's disease brain. Clin Neuropathol 20:60-63. (Pubitemid 32234485)
3. Backstrom JR, Lim GP, Cullen MJ, and Tökés ZA (1996) Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J Neurosci 16:7910-7919.
4. Deb S and Gottschall PE (1996) Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. J Neurochem 66:1641-1647. (Pubitemid 26090566)
5. Deb S, Wenjun Zhang J, and Gottschall PE (2003) Beta-Amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes. Brain Res 970:205-213. (Pubitemid 36423196)
6. Ethell DW, Kinloch R, and Green DR (2002) Metalloproteinase shedding of Fas ligand regulates beta-amyloid neurotoxicity. Curr Biol 12:1595-1600. (Pubitemid 35044846)
7. Galardy RE, Cassabonne ME, Giese C, Gilbert JH, Lapierre F, Lopez H, Schaefer ME, Stack R, Sullivan M, and Summers B (1994) Low molecular weight inhibitors in corneal ulceration. Ann N Y Acad Sci 732:315-323.
8. Hardy J and Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356. (Pubitemid 34790756)
9. Harkany T, Abrahám I, Timmerman W, Laskay G, Tóth B, Sasvári M, Kónya C, Sebens JB, Korf J, Nyakas C, et al. (2000) Beta-Amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci 12:2735-2745. (Pubitemid 30690662)
10. Howell S, Nalbantoglu J, and Crine P (1995) Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism. Peptides 16:647-652.
11. Jourquin J, Tremblay E, Décanis N, Charton G, Hanessian S, Chollet AM, Le Diguardher T, Khrestchatisky M, and Rivera S (2003) Neuronal activitydependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate. Eur J Neurosci 18:1507-1517. (Pubitemid 37215104)
12. Kim YS, Kim SS, Cho JJ, Choi DH, Hwang O, Shin DH, Chun HS, Beal MF, and Joh TH (2005) Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. J Neurosci 25:3701-3711. (Pubitemid 40503697)
13. Kurochkin IV and Goto S (1994) Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett 345:33-37. (Pubitemid 2091431)
14. Lo EH, Wang X, and Cuzner ML (2002) Extracellular proteolysis in brain injury and inflammation: role for plasminogen activations and matrix metalloproteinases. J Neurosci Res 69:1-9. (Pubitemid 34734159)
15. Malm T, Ort M, Tähtivaara L, Jukarainen N, Goldsteins G, Puolivä li J, Nurmi A, Pussinen R, Ahtoniemi T, Miettinen TK, et al. (2006) Beta-Amyloid infusion results in delayed and age-dependent learning deficits without role of inflammation or beta-amyloid deposits. Proc Natl Acad Sci U S A 103:8852-8857.
16. Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, and Quack G (2002) Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res 958:210-221. (Pubitemid 35441230)
17. Meighan SE, Meighan PC, Choudhury P, Davis CJ, Olson ML, Zornes PA, Wright JW, and Harding JW (2006) Effects of extracellular matrix-degrading proteases matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity. J Neurochem 96:1227-1241.
18. Mizoguchi H, Takuma K, Fukakusa A, Ito Y, Nakatani A, Ibi D, Kim HC, and Yamada K (2008) Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice. Psychopharmacology (Berl) 196:233-241.
19. Mizoguchi H, Yamada K, Mouri A, Niwa M, Mizuno T, Noda Y, Nitta A, Itohara S, Banno Y, and Nabeshima T (2007a) Role of matrix metalloproteinase and tissue inhibitor of MMP in methamphetamine-induced behavioral sensitization and reward: implications for dopamine receptor down-regulation and dopamine release. J Neurochem 102:1548-1560. (Pubitemid 47256194)
20. Mizoguchi H, Yamada K, Niwa M, Mouri A, Mizuno T, Noda Y, Nitta A, Itohara S, Banno Y, and Nabeshima T (2007b) Reduction of methamphetamine-induced sensitization and reward in matrix metalloproteinase-2 and -9-deficient mice. J Neurochem 100:1579-1588. (Pubitemid 46376198)
21. Mouri A, Noda Y, Hara H, Mizoguchi H, Tabira T, and Nabeshima T (2007) Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J 21:2135-2148. (Pubitemid 47026449)
22. Muir EM, Adcock KH, Morgenstern DA, Clayton R, von Stillfried N, Rhodes K, Ellis C, Fawcett JW, and Rogers JH (2002) Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes. Brain Res Mol Brain Res 100:103-117. (Pubitemid 34465583)
23. Nagy V, Bozdagi O, Matynia A, Balcerzyk M, Okulski P, Dzwonek J, Costa RM, Silva AJ, Kaczmarek L, and Huntley GW (2006) Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J Neurosci 26: 1923-1934. (Pubitemid 43295844)
24. Selkoe DJ and Schenk D (2003) Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43:545-584.
25. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, et al. (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8:1051-1058. (Pubitemid 41061516)
26. Szklarczyk A, Lapinska J, Rylski M, McKay RD, and Kaczmarek L (2002) Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. J Neurosci 22:920-930. (Pubitemid 34141772)
27. Takuma K, Yan SS, Stern DM, and Yamada K (2005a) Mitochondrial dysfunction, endoplasmic reticulum stress, and apoptosis in Alzheimer's disease. J Pharmacol Sci 97:312-316. (Pubitemid 40515744)
28. Takuma K, Yao J, Huang J, Xu H, Chen X, Luddy J, Trillat AC, Stern DM, Arancio O, and Yan SS (2005b) ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB J 19:597-598. (Pubitemid 40471256)
29. Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, et al. (1998) Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. J Med Chem 41:640-649. (Pubitemid 28093097)
30. Tian L, Stefanidakis M, Ning L, Van Lint P, Nyman-Huttunen H, Libert C, Itohara S, Mishina M, Rauvala H, and Gahmberg CG (2007) Activation of NMDA receptors promotes dendritic spine development through MMP-mediated ICAM-5 cleavage. J Cell Biol 178:687-700. (Pubitemid 47267279)
31. Tran MH, Yamada K, Olariu A, Mizuno M, Ren XH, and Nabeshima T (2001) Amyloid beta-peptide induces nitric oxide production in rat hippocampus: association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitors. FASEB J 15:1407-1409.
32. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, and Opdenakker G (2002) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase- 9 (MMP-9). Crit Rev Biochem Mol Biol 37:375-536. (Pubitemid 36071972)
33. Wang D, Noda Y, Zhou Y, Mouri A, Mizoguchi H, Nitta A, Chen W, and Nabeshima T (2007) The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25-35 i.c.v.-injected mice: involvement of dopaminergic systems. Neuropsychopharmacology 32:1261-1271. (Pubitemid 46788859)
34. Wang J and Tsirka SE (2005) Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage. Brain 128:1622-1633. (Pubitemid 41373681)
35. Wenk GL (2006) Neuropathologic changes in Alzheimer's disease: potential targets for treatment. J Clin Psychiatry 67:3-7.
36. Yamada K and Nabeshima T (2000) Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacol Ther 88:93-113. (Pubitemid 32057133)
37. Yamada K, Takayanagi M, Kamei H, Nagai T, Dohniwa M, Kobayashi K, Yoshida S, Ohhara T, Takuma K, and Nabeshima T (2005) Effects of memantine and donepezil on amyloid beta-induced memory impairment in a delayed-matching to position task in rats. Behav Brain Res 162:191-199. (Pubitemid 40828531)
38. Yamada K, Tanaka T, Han D, Senzaki K, Kameyama T, and Nabeshima T (1999) Protective effects of idebenone and alpha-tocopherol on beta-amyloid-(1-42)- induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo. Eur J Neurosci 11:83-90. (Pubitemid 29012313)
39. Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF, Turk JW, Xu J, et al. (2006) Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem 281:24566-24574. (Pubitemid 44274231)
40. Yong VW, Power C, Forsyth P, and Edwards DR (2001) Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2:502-511. (Pubitemid 33676585)